EUVIMEDEUVIMED entdecken
Open Access

Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival

Josephine M N Lopes Cardozo iD, Irene L Andrulis iD, Stig E Bojesen iD, Thilo Dörk iD, Diana M Eccles iD, Peter A Fasching iD, Maartje J Hooning iD, Renske Keeman iD, Heli Nevanlinna, Emiel J T Rutgers iD, Douglas F Easton iD, Per Hall iD und 4 weitere

Journal of Clinical Oncology · 01.04.2023 · 41 (10) · 1849-1863

DOI: 10.1200/jco.22.01978 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.04.2023. Verfasst von Josephine M N Lopes Cardozo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE A polygenic risk score (PRS) consisting of 313 common genetic variants (PRS 313 ) is associated with risk of breast cancer and contralateral breast cancer. This study aimed to evaluate the association of the PRS 313 with clinicopathologic characteristics of, and survival following, breast cancer. METHODS Women with invasive breast cancer were included, 98,397 of European ancestry and 12,920 of Asian ancestry, from the Breast Cancer Association Consortium (BCAC), and 683 women from the European MINDACT trial. Associations between PRS 313 and clinicopathologic characteristics, including the 70-gene signature for MINDACT, were evaluated using logistic regression analyses. Associations of PRS 313 (continuous, per standard deviation) with overall survival (OS) and breast cancer–specific survival (BCSS) were evaluated with Cox regression, adjusted for clinicopathologic characteristics and treatment. RESULTS The PRS 313 was associated with more favorable tumor characteristics. In BCAC, increasing PRS 313 was associated with lower grade, hormone receptor–positive status, and smaller tumor size. In MINDACT, PRS 313 was associated with a low risk 70-gene signature. In European women from BCAC, higher PRS 313 was associated with better OS and BCSS: hazard ratio (HR) 0.96 (95% CI, 0.94 to 0.97) and 0.96 (95% CI, 0.94 to 0.98), but the association disappeared after adjustment for clinicopathologic characteristics (and treatment): OS HR, 1.01 (95% CI, 0.98 to 1.05) and BCSS HR, 1.02 (95% CI, 0.98 to 1.07). The results in MINDACT and Asian women from BCAC were consistent. CONCLUSION An increased PRS 313 is associated with favorable tumor characteristics, but is not independently associated with prognosis. Thus, PRS 313 has no role in the clinical management of primary breast cancer at the time of diagnosis. Nevertheless, breast cancer mortality rates will be higher for women with higher PRS 313 as increasing PRS 313 is associated with an increased risk of disease. This information is crucial for modeling effective stratified screening programs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsFemaleHumansRisk FactorsPrognosisProportional Hazards ModelsBreast

Autor:innen und Institutionen

  • Department of Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium.
  • Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
  • Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.

ORCID-Profile: Josephine M N Lopes Cardozo, Irene L Andrulis, Stig E Bojesen, Thilo Dörk, Diana M Eccles, Peter A Fasching, Maartje J Hooning, Renske Keeman, Emiel J T Rutgers, Douglas F Easton, Per Hall, Laura J van 't Veer, Marjanka K Schmidt

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS
  • Cancer Research UK
  • WHI NIH HHS
  • Wellcome Trust
  • NIEHS NIH HHS
  • NCCDPHP CDC HHS
  • Medical Research Council

Zitieren

APA

Lopes Cardozo, J. M. N., Andrulis, I. L., Bojesen, S. E., Dörk, T., Eccles, D. M., Fasching, P. A., Hooning, M. J., Keeman, R., Nevanlinna, H., Rutgers, E. J. T., Easton, D. F., Hall, P., Pharoah, P. D. P., van 't Veer, L. J., Schmidt, M. K., & Breast Cancer Association Consortium and MINDACT Collaborators (2023). Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival. Journal of Clinical Oncology, 41(10), 1849-1863. https://doi.org/10.1200/jco.22.01978

Vancouver

Lopes Cardozo JMN, Andrulis IL, Bojesen SE, Dörk T, Eccles DM, Fasching PA, et al. Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival. Journal of Clinical Oncology. 2023;41(10):1849-1863. doi:10.1200/jco.22.01978

BibTeX
@article{LopesCardozo2023,
  author = {Lopes Cardozo, Josephine M N and Andrulis, Irene L and Bojesen, Stig E and Dörk, Thilo and Eccles, Diana M and Fasching, Peter A and Hooning, Maartje J and Keeman, Renske and Nevanlinna, Heli and Rutgers, Emiel J T and Easton, Douglas F and Hall, Per and Pharoah, Paul D P and van 't Veer, Laura J and Schmidt, Marjanka K and Breast Cancer Association Consortium and MINDACT Collaborators, Breast Cancer Association Consortium and MINDACT Collaborators},
  title = {Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {10},
  pages = {1849--1863},
  doi = {10.1200/jco.22.01978}
}
Kostenlos starten →